Vicebio

🗓 Founded 2019👥 10 employees💰 Last funded Sep 2024
Biotechnology Research
LinkedIn
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Vicebio?
Vicebio has 1 investors on record on gritt.io, 1 mid-stage.
When did Vicebio last raise funding?
The most recent investment in Vicebio recorded on gritt.io was in September 2024.
When was Vicebio founded?
Vicebio was founded in 2019.
What industry is Vicebio in?
Vicebio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.